AMILORIDE ( DrugBank: Amiloride )

4 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	5
67	Polycystic kidney disease	2
225	Congenital nephrogenic diabetes insipidus	3
299	Cystic fibrosis	3

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01910259 (ClinicalTrials.gov)	December 18, 2014	19/7/2013	MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial	A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.	Secondary Progressive Multiple Sclerosis	Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo	University College, London	Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick	Completed	25 Years	65 Years	All	445	Phase 2	United Kingdom
2	EUCTR2012-005394-31-GB (EUCTR)	01/04/2014	05/09/2014	MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMS	MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial	Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rilutek Product Name: Rilutek INN or Proposed INN: Riluzole Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: Amiloride Trade Name: Fluoxetine Product Name: Fluoxetine INN or Proposed INN: Fluoxetine hydrochloride	UCL	NULL	Not Recruiting			Female: yes Male: yes	440	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
3	EUCTR2012-005113-39-AT (EUCTR)	08/04/2013	18/02/2013	Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve.	A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis - Amiloride Hydrochlorothiazide in acute autoimmune optic neuritis	Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Amilostad HCT Product Name: Amilostad HCT tablets INN or Proposed INN: AMILORIDE HYDROCHLORIDE, 2 H2O Other descriptive name: Amiloride Hydrochloride INN or Proposed INN: hydrochlorothiazide Other descriptive name: HYDROCHLOROTHIAZIDE	Universitätsklinik für Neurologie, Medizinische Universität Wien	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Austria
4	NCT01802489 (ClinicalTrials.gov)	February 2013	27/2/2013	Amiloride Clinical Trial In Optic Neuritis	A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis	Optic Neuritis;Multiple Sclerosis	Drug: Amiloride;Drug: Placebo	University of Oxford	Multiple Sclerosis Society of Great Britain and Northern Ireland	Completed	18 Years	55 Years	All	46	Phase 2	United Kingdom
5	EUCTR2007-004051-11-GB (EUCTR)	18/12/2008	15/07/2008	Amiloride Treatment in Multiple Sclerosis - Amiloride in MS	Amiloride Treatment in Multiple Sclerosis - Amiloride in MS	Multiple Sclerosis	Trade Name: Amiloride Product Name: Amiloride Hydrochloride	Oxford Racliffe NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	23		United Kingdom

67. Polycystic kidney disease

Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05228574 (ClinicalTrials.gov)	March 11, 2022	12/1/2022	Treatment of Vascular Stiffness in ADPKD	Treatment of Vascular Stiffness in Patients With Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney	Dietary Supplement: Sodium chloride (NaCl);Dietary Supplement: Placebo;Drug: Amiloride Hcl 5mg Tab	Erasmus Medical Center	NULL	Recruiting	18 Years	N/A	All	54	Phase 4	Netherlands
2	EUCTR2020-000433-40-NL (EUCTR)	30/12/2021	03/08/2021	Treatment of stiffness in blood vessels in patients with familial cystic kidney disease	Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease - TRAMPOLINE	Autosomal dominant polycystic kidney disease;Therapeutic area: Not possible to specify	Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: AMILORIDE Trade Name: Sodium Chloride INN or Proposed INN: Sodium chloride Other descriptive name: Sodium Chloride	Erasmus University Medical Centre Rotterdam	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	54	Phase 4	Netherlands

225. Congenital nephrogenic diabetes insipidus

Clinical trials : 15 / Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05044611 (ClinicalTrials.gov)	January 11, 2023	27/8/2021	AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium	AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled Trial	Bipolar Disorder	Drug: Anhydrous Amiloride Hydrochloride;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	70 Years	All	148	Phase 4	France
2	NCT00478335 (ClinicalTrials.gov)	May 2007	23/5/2007	Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus	Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus	Nephrogenic Diabetes Insipidus	Drug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitonin	University of Colorado, Denver	University of Aarhus	Completed	5 Years	25 Years	Male	4	N/A	United States;Denmark
3	EUCTR2006-001202-84-NL (EUCTR)	01/02/2007	31/01/2007	Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI	Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI	Lithium-induced Nephrogenic Diabetes Insipidus MedDRA version: 9.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic	Trade Name: Midamor Product Name: Amiloride Trade Name: Hydrochloorthiazide Product Name: hydrochloorthiazide	Radboud University Nijmegen Medical Centre	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 4	Netherlands

299. Cystic fibrosis

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00547053 (ClinicalTrials.gov)	December 2006	17/10/2007	Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis	A Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Amiloride Solution for Inhalation	Children's Hospital Boston	Cystic Fibrosis Foundation Therapeutics	Completed	6 Years	N/A	Both	25	Phase 1	United States
2	NCT00274391 (ClinicalTrials.gov)	July 2001	9/1/2006	Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis	Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis	Cystic Fibrosis	Drug: 7% NaCl;Drug: Amiloride HCl	University of North Carolina	Cystic Fibrosis Foundation Therapeutics	Completed	14 Years	N/A	Both	24	Phase 2	United States
3	NCT00004705 (ClinicalTrials.gov)	September 1996	24/2/2000	Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis		Cystic Fibrosis	Drug: amiloride;Drug: uridine	FDA Office of Orphan Products Development	University of North Carolina	Completed	4 Years	N/A	Both		N/A	NULL